SQZ Biotechnologies Company (SQZ)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against SQZ Biotechnologies Company (“SQZ” or “the Company”) (NYSE: SQZ). Investors who purchased SQZ securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether SQZ violated federal securities laws.
On or around October 29, 2022, SQZ conducted its initial public offering (“IPO”), selling 4,411,765 shares priced at $16.00 per share. Then, on December 1, 2022, SQZ issued a press release “announc[ing] that Armon Sharei, PhD, Chief Executive Officer at SQZ Biotechnologies, will step down from his role as CEO and the Board of Directors, effective immediately,” and that the Company will reduce its workforce by roughly 60% as it “pause[s] its APC, Activating Antigen Carrier (AAC) and Tolerizing Antigen Carrier (TAC) programs.” On this news, SQZ’s stock price fell sharply during intraday trading on December 1, 2022.
If you are aware of any facts relating to this investigation or purchased SQZ securities, you can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.